Long-COVID versus adverse event following COVID vaccination among students and staff of tertiary care teaching hospital


  • Tanuja B. Javadekar Faculty, Medical College Baroda, Vadodara, Gujarat, India
  • Bhavin P. Barai Faculty, Medical College Baroda, Vadodara, Gujarat, India
  • Chirag B. Mistry Faculty, Medical College Baroda, Vadodara, Gujarat, India
  • Ishaan Sareen Intern Doctor, Medical College Baroda, Vadodara, Gujarat, India
  • Riya Vaishnav Intern Doctor, Medical College Baroda, Vadodara, Gujarat, India




Adverse event following immunization, COVID19, Cross-sectional study, Healthcare staff, Long COVID


Background: Long COVID is an important public health concern requiring proper defining, quantifying and describing following SARS-CoV infection with differentiation from adverse events due to COVID vaccination. So, this study was planned to analyze adverse effect of COVID19 vaccination or drug for COVID treatment versus consequences of COVID19 infection.

Methods: Self-reported data was collected through questionnaire-based survey by voluntary participation of healthcare staff. Percentage of participant developing various events was analyzed by enlisting sign, symptom, co-morbidity and medication history. Association between COVID-19 infection with number of doses of COVID-19 vaccine taken was analyzed by Chi Square Test with p value <0.05. Association between presence of specific sign, symptom after COVID infection or side effect after COVID vaccination was analyzed by Chi-Square Test with p value <0.05. 

Results: Overall total 985 (59.58%) participants were analyzed and among them maximum number of participants (60.30%) reported as COVID-19 positive during the third wave with history of diagnosed COVID positive twice (57.87%). Participants with presence of co-morbidity were more likely to develop symptoms (p<0.001). On analysis, fever, body ache, headache, sore throat and fatigue were significantly more likely to develop after COVID infection as compared to after COVID vaccination (p<0.001). 

Conclusions: This study by exploratory survey highlights heterogeneity of Long COVID sign or symptom that’s seen predominantly in person with co-morbidity and a few of them were mimicking adverse events after COVID vaccinations.



Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. ClinMicrobiol Infect 2021; 27(1): 89–95.

Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 11, 16144 (2021).

Hannah Ritchie EO-O, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie Macdonald, Charlie Giattino, and Max Roser. Coronavirus Pandemic (COVID-19). 2021.

Townsend L, Dowds J, O’Brien K, et al. Persistent Poor Health Post-COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am ThoracSoc 2021.

Vink M, Vink-Niese A. Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome.Healthcare (Basel) 2020; 8(4).

Lamprecht B. [Is there a post-COVID syndrome?]. Pneumologe (Berl) 2020: 1–4.

Kingstone T, Taylor AK, O’Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the ‘right’ GP: a qualitative study of the experiences of people with long-COVID. BJGP Open 2020; 4(5).

Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status.Respirology 2010; 15(3): 543–50.

Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2020.

Carfi A, Bernabei R, Landi F, GemelliAgainst C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020; 324(6): 603–5.

GemelliAgainst C-P-ACSG. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging ClinExp Res 2020; 32(8): 1613–20.

Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020; 370: m3026.

Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6(4).

Alwan NA. Track COVID-19 sickness, not just positive tests and deaths. Nature 2020; 584(7820): 170.

Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69(30): 993–8.

Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020; 81(6): e4–e6.

Dosch S. F., Mahajan S. D., Collins A. R. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro. Virus Research .( 2009) ;142(1-2):19–27. doi: 10.1016/j.virusres.2009.01.005.

Gil-Del-Valle L, Gravier-Hernández R, Baldoquin-Rodríguez W, et al. Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020. AdvPharmacol Pharm Sci. 2023 Feb 1;2023:1995642. doi: 10.1155/2023/1995642. PMID: 36776283; PMCID: PMC9908337.

El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. (2021);385(19):1774–85.

Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72314 cases from the Chinese Center for disease control and prevention. JAMA (2020) 323, 1239–1242.

Li, X. & Ma, X. Acute respiratory failure in COVID-19: Is it “typical” ARDS?. Crit. Care. (2020) 24, 198.

Bikdeli, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. (2020) 75, 295073.

Helms, J. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive. Care Med. 46, 1089–1098 (2020).

Shah, W., Hillman, T., Playford, E. D. &Hishmeh, L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 372, n136 (2021).

Mahase, E. Covid-19: what do we know about “long covid”?. BMJ (2020) 370, m2815.

Callard, F. &Perego, E. How and why patients made long Covid. Soc. Sci Med.(2021) 268, 113426.

Halpin, S. J. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J. Med. Virol.(2021) 93, 1013–1022.

Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (2021) 397, 220–232.

Miyazato, Y. et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open. Forum Infect. Dis. 7, ofaa507 (2020).

Ao D, Lan T, He X, Liu J, Chen L, Baptista-Hon DT, Zhang K, Wei X. SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm (2020). 2022 Mar 16;3(1):e126. doi: 10.1002/mco2.126. PMID: 35317190; PMCID: PMC8925644

Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS‐CoV‐2 spike cross‐recognize Omicron. Nature. Published online January 31, 2022. 10.1038/s41586-022-04460-3

Revised Guidelines for clinical management of Covid-19. DGHS (EMR Division), MoHFw, Govt. of India. 2020. Available from htps//www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf

Cooney J, Appiahene P, Findlay R, Al-Hillawi L, Rafique K, Laband W, Shandro B, Poullis A. COVID-19 infection causing residual gastrointestinal symptoms - a single UK centre case series. Clin Med (Lond). 2022 Mar;22(2):181-183. doi: 10.7861/clinmed.2021-0522. Epub 2022 Feb 1. PMID: 35105680; PMCID: PMC8966828.

Choudhury A, Tariq R, Jena A, Vesely EK, Singh S, Khanna S, Sharma V. Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. TherapAdvGastroenterol. 2022 Aug 19;15:17562848221118403. doi: 10.1177/17562848221118403. PMID: 36004306; PMCID: PMC9393939.

Gautam N, Madathil S, Tahani N, Bolton S, Parekh D, Stockley J, Goyal S, Qureshi H, Yasmin S, Cooper BG, et al. Medium-term outcome of severe to critically ill patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis. 2021;74:301–308. doi: 10.1093/cid/ciab341.

Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. ClinMicrobiol Infect 2020.

Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 350: g7647.

Horvath L, Lim JWJ, Taylor JW, et al. Smell and taste loss in COVID-19 patients: assessment outcomes in a Victorian population. ActaOtolaryngol 2020: 1–5.

Wang, X. et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. Q. J. Med. 113, 657–665 (2020).

Munro KJ, Uus K, Almufarrij I, Chaudhuri N, Yioe V. Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. Int J Audiol 2020; 59(12): 889–90.




How to Cite

Javadekar, T. . B., Barai, B. P., Mistry, C. B., Sareen, I., & Vaishnav, R. (2023). Long-COVID versus adverse event following COVID vaccination among students and staff of tertiary care teaching hospital . International Journal of Basic & Clinical Pharmacology, 12(5), 712–721. https://doi.org/10.18203/2319-2003.ijbcp20232569



Original Research Articles